Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RO5045377 + cytarabine
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
RO5045377 + cytarabine is an investigational combination therapy for acute myeloid leukemia (AML) in which RO5045377, a small-molecule inhibitor developed by Roche, is administered together with cytarabine, a well-established antimetabolite chemotherapy. RO5045377 is an oral agent, with phase 1 studies evaluating its maximum tolerated dose, safety, and efficacy in combination with cytarabine in AML patients. Cytarabine acts primarily by inhibiting DNA polymerase, leading to the cessation of DNA synthesis and ultimately inducing apoptosis in rapidly dividing cells. The combination is being studied due to the potential for synergistic effects on leukemic cell proliferation and improved anti-leukemic activity.
- Other names
- RO5045337 + cytarabine
02
Targets
DNA polymerase familyWEE1 (WEE1 G2 checkpoint kinase)
Beyond the preview
Go deeper on RO5045377 + cytarabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RO5045377 + cytarabine.